Aug 28 (Reuters) - Csl Ltd
* CSL Behring acquires us biotech company calimmune-csl.ax
* Deal for an upfront payment of $91 million.
* Additionally, CSL Behring will acquire two proprietary platform technologies, Select and Cytegrity
* Additional research and development expenditure is expected to be contained within CSL’s previously announced guidance
* CSL Behring will have operational control of Calimmune following closing of transaction
* deal includes potential for milestone payments of up to $325 million over a period anticipated to be around eight years or more following closing Source text for Eikon: Further company coverage: